
GOING BEYOND ANTIBIOTICS®
DEVELOPING ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States.
Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging.
We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China.
In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.
DEVELOPING ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States.
Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging.
We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China.
In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.
Location: Canada, Ontario, Emeryville
Employees: 11-50
Phone: +1 510-899-8800
Founded date: 2000
Investors 1
Date | Name | Website |
- | TRITON FUN... | tritonfund... |
Mentions in press and media 5
Date | Title | Description |
13.03.2024 | NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals | - |
20.01.2022 | NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks | NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces its commitment to donat... |
13.12.2021 | NovaBay Pharmaceuticals : DERMAdoctor's Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance | EMERYVILLE, Calif. (December 13, 2021) - NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare m... |
12.11.2021 | Press Release, dated November 8, 2021 - Form 8-K | Company to hold third quarter 2021 earnings call on November 11 and will discuss plans for the combined companies EMERYVILLE, Calif. (November 8, 2021) - NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the closing of the previ... |
28.09.2021 | NovaBay Pharmaceuticals : Operational synergies and diversified product portfolio expected to drive profitability (Form 8-K) | Operational synergies and diversified product portfolio expected to drive profitability Conference Call Wednesday at 1:30 p.m. Pacific time EMERYVILLE, Calif. (September 28, 2021) - NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announ... |